- Home
- GNLX vs APLT Comparison
GNLX vs APLT Comparison
Compare GNLX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- APLT
- Stock Information
- Founded
- GNLX 2001
- APLT 2016
- Country
- GNLX United States
- APLT United States
- Employees
- GNLX N/A
- APLT N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- APLT Health Care
- Exchange
- GNLX Nasdaq
- APLT Nasdaq
- Market Cap
- GNLX 110.9M
- APLT 52.9M
- IPO Year
- GNLX 2023
- APLT 2019
- Fundamental
- Price
- GNLX $3.09
- APLT $0.33
- Analyst Decision
- GNLX Strong Buy
- APLT Buy
- Analyst Count
- GNLX 4
- APLT 7
- Target Price
- GNLX $17.75
- APLT $6.10
- AVG Volume (30 Days)
- GNLX 137.5K
- APLT 2.3M
- Earning Date
- GNLX 08-13-2025
- APLT 08-06-2025
- Dividend Yield
- GNLX N/A
- APLT N/A
- EPS Growth
- GNLX N/A
- APLT N/A
- EPS
- GNLX N/A
- APLT N/A
- Revenue
- GNLX N/A
- APLT $265,000.00
- Revenue This Year
- GNLX N/A
- APLT $1,768.13
- Revenue Next Year
- GNLX N/A
- APLT $292.85
- P/E Ratio
- GNLX N/A
- APLT N/A
- Revenue Growth
- GNLX N/A
- APLT N/A
- 52 Week Low
- GNLX $1.60
- APLT $0.30
- 52 Week High
- GNLX $5.89
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- GNLX 56.10
- APLT 46.71
- Support Level
- GNLX $2.75
- APLT $0.30
- Resistance Level
- GNLX $3.17
- APLT $0.36
- Average True Range (ATR)
- GNLX 0.23
- APLT 0.03
- MACD
- GNLX -0.00
- APLT 0.00
- Stochastic Oscillator
- GNLX 56.94
- APLT 46.22
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.